Rolando Pajón joins Biofabri to strengthen final phase of tuberculosis vaccine development

Spain-based Biofabri, the human vaccines subsidiary of the biopharmaceutical group Zendal, has added Rolando Pajón Feyt (pictured, above), an international expert in immunotherapy and vaccine development, to its management team to strengthen the final phase of clinical development of its tuberculosis vaccine candidate, MTBVAC.

Dr Feyt will assume the role of chief medical and scientific officer (CMSO) at Biofabri. The addition of the vaccinologist comes at a pivotal moment for the project, marked by its progress toward the final stages of clinical evaluation and by the need to integrate science, clinical development, regulation and market access strategy.